Table 2 List of ongoing PD-1 inhibition and rituximab combination therapy studies
Study (NCT) | Phase | Patients | ICI | Study start | Study completion | Conditions treated |
|---|---|---|---|---|---|---|
NCT02541565 | 1 | 33 | Pembrolizumab | November 2015 | December 18, 2018a | DLBCL, FL |
NCT03259529 | 1/2 | 30 | Nivolumab | March 2017 | December 27, 2020 | DLBCL |
NCT03749018 | 2 | 30 | Nivolumab | January 2019 | December 31, 2021 | B-cell non-Hodgkin lymphoma |
NCT03704714 | 1/2 | 30 | Nivolumab | November 2018 | June 11, 2022 | DLBCL |
NCT03719131 | 2 | 44 | Nivolumab | June 2019 | October 31, 2022 | Stage III-IV melanoma |
NCT03630042 | 2 | 42 | Pembrolizumab | August 2019 | April, 2023 | Waldenström’s macrogloulinamia |
NCT03934814 | 1 | 88 | Pembrolizumab | May 2019 | September 23, 2023 | Solid tumors, DLBCL, indolent lymphoma |
NCT02677155 | 2 | 20 | Pembrolizumab | January 2016 | January, 2024 | FL |
NCT03245021 | 1 | 39 | Nivolumab | September 2017 | June, 2024 | FL |
NCT03995147 | 2 | 51 | Pembrolizumab | August 2019 | August 20, 2024 | DLBCL |
NCT03121677 | 1 | 20 | Nivolumab | October 2018 | January 31, 2028 | FL |